Clinical Evaluation of the FluidVision Accommodating Intraocular Lens (AIOL)
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of an investigational IOL.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Eligible subjects will receive the investigational IOL in one eye and be followed at 1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months and 36 months post-operation.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: FluidVision FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery |
Device: FluidVision AIOL
Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
Procedure: Cataract Surgery
Performed using standard microsurgical techniques
|
Outcome Measures
Primary Outcome Measures
- Accommodative amplitude [Month 6]
Accommodative amplitude is a measure of the ability of the eye to focus from a target that is at distance into a target that is near.
- Best corrected distance visual acuity (BCDVA) [Month 6]
Visual acuity of the eye will be tested with the correction in place.
- Rates of adverse events [Up to Month 36]
Adverse events will be collected from time of enrollment to study exit
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Eligible for primary intraocular lens implantation for the correction of aphakia following cataract extraction;
-
Best corrected distance visual acuity worse than 20/40 either with or without a glare source present (e.g. Brightness Acuity Tester);
-
Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism;
-
Willing and able to comply with schedule for follow-up visits for 36 months after surgery.
-
Other protocol-defined inclusion criteria may apply.
Key Exclusion Criteria:
-
Systemic disease that could increase the operative risk or confound the outcome (e.g. autoimmune disease, diabetes);
-
Taking systemic medications that may confound the outcome or increase the risk to the subject;
-
Ocular conditions that may predispose for future complications;
-
Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject;
-
Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes;
-
Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future best corrected visual acuity loss worse than 20/40.
-
Other protocol-defined exclusion criteria may apply.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | PowerVision Investigative Site | Heidelberg | Baden-Württemberg | Germany | D-69120 |
2 | PowerVision Investigative Site | Stuttgart | Baden-Württemberg | Germany | D-70176 |
3 | PowerVision Investigative Site | Bochum | North Rhine-Westphalia | Germany | 44892 |
4 | PowerVision Investigative Site | Berlin | Germany | 10559 | |
5 | PowerVision Investigative Site | Claremont | Cape Town | South Africa | 7708 |
6 | PowerVision Investigative Site | Northcliff | Johannesburg | South Africa | 2195 |
7 | PowerVision Investigative Site | Queenswood | Pretoria | South Africa | 2001 |
8 | PowerVision Investigative Site | Paardevlei | Somerset West | South Africa | 7130 |
Sponsors and Collaborators
- PowerVision
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AIOL-2009-1